Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

2(40.0%)

Phase 1

1(20.0%)

5Total

Phase 2(2)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02110147Phase 3Completed

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Role: lead

NCT01432301Unknown

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Role: lead

NCT00024427Phase 3Completed

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Role: lead

NCT00110864Phase 2Completed

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

Role: lead

NCT00110851Phase 2Completed

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Role: lead

NCT00044785Phase 1Terminated

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Role: lead

All 6 trials loaded